- Home
- AIV vs SYRE Comparison
AIV vs SYRE Comparison
Compare AIV & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIV
- SYRE
- Stock Information
- Founded
- AIV 1975
- SYRE 2013
- Country
- AIV United States
- SYRE United States
- Employees
- AIV N/A
- SYRE N/A
- Industry
- AIV Real Estate Investment Trusts
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- AIV Real Estate
- SYRE Health Care
- Exchange
- AIV Nasdaq
- SYRE Nasdaq
- Market Cap
- AIV 1.3B
- SYRE 1.3B
- IPO Year
- AIV 1994
- SYRE 2016
- Fundamental
- Price
- AIV $8.95
- SYRE $21.29
- Analyst Decision
- AIV
- SYRE Strong Buy
- Analyst Count
- AIV 0
- SYRE 8
- Target Price
- AIV N/A
- SYRE $51.50
- AVG Volume (30 Days)
- AIV 1.1M
- SYRE 574.3K
- Earning Date
- AIV 02-24-2025
- SYRE 03-03-2025
- Dividend Yield
- AIV 6.70%
- SYRE N/A
- EPS Growth
- AIV N/A
- SYRE N/A
- EPS
- AIV N/A
- SYRE N/A
- Revenue
- AIV $204,735,000.00
- SYRE N/A
- Revenue This Year
- AIV N/A
- SYRE $168.62
- Revenue Next Year
- AIV $6.56
- SYRE $47.61
- P/E Ratio
- AIV N/A
- SYRE N/A
- Revenue Growth
- AIV 13.91
- SYRE N/A
- 52 Week Low
- AIV $7.06
- SYRE $20.13
- 52 Week High
- AIV $9.49
- SYRE $47.97
- Technical
- Relative Strength Index (RSI)
- AIV 52.69
- SYRE 40.66
- Support Level
- AIV $8.81
- SYRE $21.61
- Resistance Level
- AIV $9.01
- SYRE $23.04
- Average True Range (ATR)
- AIV 0.15
- SYRE 1.43
- MACD
- AIV -0.01
- SYRE -0.03
- Stochastic Oscillator
- AIV 66.67
- SYRE 22.03
About AIV Apartment Investment and Management Company
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. The company generates majority of revenue from operating segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.